Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.
Mol Biomed
; 2(1): 29, 2021.
Article
in English
| MEDLINE | ID: covidwho-1515465
ABSTRACT
In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates, PIKA adjuvanted S-trimer induced high SARS-CoV-2 neutralization titers and protected from virus replication in the lung following SARS-CoV-2 challenge. In addition, the long-term neutralizing antibody response induced by S-trimer vaccine adjuvanted by PIKA could neutralize multiple SARS-CoV-2 variants and there is no obvious different among the SARS- CoV-2 variants of interest or concern, including B.1.351, B.1.1.7, P.1, B.1.617.1 and B.1.617.2 variants. These data support the utility of S-trimer protein adjuvanted by PIKA as a potential vaccine candidate against SARS-CoV-2 infection. Supplementary Information The online version contains supplementary material available at 10.1186/s43556-021-00054-z.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Long Covid
/
Vaccines
/
Variants
Language:
English
Journal:
Mol Biomed
Year:
2021
Document Type:
Article
Affiliation country:
S43556-021-00054-z
Similar
MEDLINE
...
LILACS
LIS